drugset / Trial / NCT02870569
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).
Timeline
- Start
- 2016-09
- Primary completion
- 2018-07-02
- Completion
- 2018-12
Publications
- Sun D, Zhang X, Jin X, Shi C, Sun Y, Zhang Y, Liang J, Lin Y. BRAFV600E mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials. Thyroid Res. 2025 Feb 10;18(1):5. doi: 10.1186/s13044-025-00223-0.
- Lin YS, Yang H, Ding Y, Cheng YZ, Shi F, Tan J, Deng ZY, Chen ZD, Wang RF, Ji QH, Huang R, Li LF. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial. Thyroid. 2021 Apr;31(4):607-615. doi: 10.1089/thy.2020.0235. Epub 2020 Oct 15.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 200 mg | Oral |
| Subject | Donafenib | Small molecule | 300 mg | Oral |